What is the appropriate treatment for vaginal Candida glabrata or Candida krusei infection?

Treatment of Vaginal Candida glabrata/krusei

For vaginal C. glabrata or C. krusei infections, avoid oral fluconazole as these species are inherently azole-resistant; instead, use topical intravaginal boric acid 600 mg daily for 14 days as first-line therapy, with topical flucytosine cream (17% alone or combined with 3% amphotericin B cream) as second-line treatment for refractory cases. 1

Understanding the Problem

C. glabrata and C. krusei represent "complicated" vulvovaginal candidiasis because they are non-albicans species with inherent resistance patterns that make standard azole therapy ineffective 1. C. krusei is completely resistant to fluconazole, while C. glabrata demonstrates dose-dependent susceptibility at best, with frequent treatment failures even with high-dose azoles 1, 2.

Treatment Algorithm

First-Line Therapy: Topical Boric Acid

• Intravaginal boric acid 600 mg in gelatin capsules daily for 14 days 1
• This achieves clinical and mycologic success in 64-71% of symptomatic women 3
• Must be compounded by a pharmacist specifically for vaginal use
• Local side effects are uncommon 3
• Do not extend beyond 14 days - no additional benefit observed with longer courses 3

Second-Line Therapy: Topical Flucytosine

If boric acid fails or symptoms persist:

• Topical 17% flucytosine cream alone OR combined with 3% amphotericin B cream, applied intravaginally daily for 14 days 1
• Achieves 90% success rate in azole-refractory cases 3
• Requires compounding by pharmacist 1
• The combination formulation may be superior for resistant cases 4

Third-Line Option: Nystatin

• Nystatin intravaginal suppositories 100,000 units daily for 14 days 1
• Less effective than boric acid or flucytosine but more readily available in some regions
• Note: Not available in all countries (e.g., UK) 5

Critical Clinical Considerations

Confirm True Infection vs. Colonization

The most important initial decision is determining whether C. glabrata/krusei represents true infection requiring treatment versus colonization in a patient with another condition 1. Look for:

• Active symptoms: pruritus, burning, vaginal soreness, dyspareunia, dysuria
• Physical findings: vulvar edema, erythema, excoriation, fissures
• Microscopy showing yeast/hyphae with normal vaginal pH (4.0-4.5) 1

Why Oral Azoles Fail

Do not use oral fluconazole, itraconazole, voriconazole, or posaconazole as monotherapy - these frequently fail for C. glabrata and are completely ineffective for C. krusei 1, 6. Even high-dose fluconazole (800 mg/day for 2-3 weeks) shows poor efficacy 2.

Recurrent Infections

For recurrent C. glabrata/krusei vulvovaginitis:

1. Re-treat with 14 days of boric acid or flucytosine
2. Consider maintenance suppression (though evidence is limited for non-albicans species)
3. Investigate underlying risk factors: diabetes, immunosuppression, antibiotic use 2

Common Pitfalls to Avoid

1. Don't prescribe standard 3-7 day azole courses - these will fail and delay appropriate treatment
2. Don't use single-dose fluconazole 150 mg - completely ineffective for these species 1
3. Don't confuse with C. albicans treatment - requires species-specific therapy
4. Don't treat asymptomatic colonization - only treat documented symptomatic infection 1
5. Don't extend boric acid beyond 14 days - no additional benefit and increases side effect risk 3

Pregnancy Considerations

Topical boric acid and flucytosine have limited safety data in pregnancy. In pregnant patients with C. glabrata/krusei:

• Topical nystatin is the safest option, though less effective
• Avoid systemic azoles (teratogenic)
• Consider consultation with maternal-fetal medicine for refractory cases

Emerging Resistance

C. glabrata and C. krusei show increasing echinocandin tolerance in systemic infections 7, though this primarily affects invasive disease rather than vulvovaginal infections. For vulvovaginal disease, topical non-azole agents remain effective 5, 3.